Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 4/20 | 0.56 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.46 |
| ▸ | TYMS | P04818 | 2/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.44 |
| ▸ | NT5C | Q8TCD5 | 1/20 | 0.41 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 3/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16871721 | 0.93 | P2RY2 (0.54) | P2RY2P2RY12TYMSIMPDH2NT5C | |
| SCHEMBL16871712 | 0.87 | P2RY2 (0.55) | P2RY2TK2TK1 | |
| SCHEMBL17363876 | 0.87 | P2RY2 (0.55) | P2RY2TK2TK1 | |
| SCHEMBL17363877 | 0.87 | P2RY2 (0.55) | P2RY2TK2TK1 | |
| SCHEMBL17369140 | 0.84 | P2RY2 (0.75) | P2RY2P2RY12TYMSIMPDH2DNPH1 | |
| SCHEMBL16871787 | 0.84 | P2RY2 (0.75) | P2RY2P2RY12TYMSIMPDH2DNPH1 | |
| SCHEMBL16871866 | 0.81 | P2RY6 (0.52) | P2RY2TYMSDNPH1TK1 | |
| SCHEMBL18486272 | 0.78 | P2RY2 (0.73) | P2RY2P2RY12IMPDH2DNPH1TK2 | |
| SCHEMBL16546792 | 0.77 | P2RY6 (0.56) | P2RY2P2RY12 | |
| SCHEMBL4145311 | 0.77 | P2RY6 (0.56) | P2RY2P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2891717-B1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO LTD (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| EP-3130597-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20150376611-A1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2891717-A1 | OLIGONUCLEOTIDE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10378011-B2 | Oligonucleotide | HNRNPA3, AGO2, RBM3 | P2RY2 4450/4885P2RY12 4787/4885TYMS 1779/4885 |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | P2RY2 2497/4885P2RY12 3118/4885TYMS 139/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | P2RY2 2562/4885P2RY12 3171/4885TYMS 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.